Saturday - June 13, 2026
Johnson & Johnson Late-Breaking Results Show Nipocalimab Significantly Reduced Systemic Lupus Erythematosus Disease Activity in a Phase 2 Study
June 04, 2026
RARITAN, New Jersey, June 4 -- Johnson and Johnson Innovative Medicine issued the following news release on June 3, 2026:

* * *

Johnson & Johnson late-breaking results show nipocalimab significantly reduced systemic lupus erythematosus (SLE) disease activity in a Phase 2 study

* Nipocalimab - the first and only neonatal Fc receptor (FcRn) blocker to be studied in systemic lupus erythematosus - is designed to target and reduce pathogenic immunoglobulin G . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your
Affiliation		 Government Newspaper / Media Business
Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions
or comments:

Click here for more information about our products

Click here for more information about our products